British specialty chemicals manufacturer Croda has completed its acquisition of Solus Biotech
This latest acquisition will enhance the company’s current synthetic ceramides portfolio delivered by Sederma, drawing on Solus’ existing biotech-derived ceramide and phospholipid technologies for the beauty markets.
Located in South Korea, Solus will expand Croda’s Asian manufacturing capability and create a new biotechnology R&D hub in the region, working in synergy with Sederma’s R&D center in Le Perray, France.
“This is a very exciting opportunity for Croda. Our existing ceramides, currently from Sederma, will be complemented by these natural fermentation-derived ceramides, furthering our portfolio of high efficacy science-based ingredients. We are pleased to add Solus’ manufacturing site in South Korea to our operations, furthering our growth strategy for this key region. Innovation synergies between our different R&D labs will bring additional technical value and business opportunities for our customers all over the world,” said Luc Emprin global business director at Croda’s Sederma.
